23:23 , Oct 19, 2018 |  BioCentury  |  Finance

CuraSen’s SPARK

After debuting with a $54.5 million series A round, CuraSen Therapeutics Inc. hopes to generate clinical proof-of-concept data for at least two neurodegenerative disease programs in the next three years. New Leaf Venture Partners led...
18:00 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round on Oct. 17 led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla...
18:23 , Oct 17, 2018 |  BC Extra  |  Financial News

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla Capital, Alta Partners,...
15:37 , May 4, 2018 |  BC Week In Review  |  Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
19:46 , Apr 30, 2018 |  BC Extra  |  Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
00:25 , Jun 21, 2017 |  BC Extra  |  Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI)...
02:10 , Feb 11, 2017 |  BioCentury  |  Product Development

Form(ulation) follows function

A clinical study of two formulations of marketed drug Linzess linaclotide supports Ironwood Pharmaceuticals Inc. ’s hypothesis that pain in irritable bowel syndrome with constipation is not due to constipation alone, but also to hypersensitive...
18:54 , Nov 4, 2016 |  BioCentury  |  Finance

Third Rock’s wellspring

By sticking to its script of forming early stage big idea companies, Third Rock Ventures raised a $616 million fund in a matter of months and believes its company-building efforts will be rewarded regardless of...
07:00 , Sep 19, 2016 |  BioCentury  |  Product Development

Getting ahead of headache

After several false starts, investments in CGRP inhibitors are bearing fruit in the clinic - if not exactly the prize pumpkins once hoped for from the class. Still, if the sponsors developing these products can...